ERWINASE® L-Asparaginase 10,000IU vials
|Name||ERWINASE® L-Asparaginase 10,000IU vials|
|Description||L-asparaginase catalyses the deamination of asparagine to aspartic acid with the release of ammonia.
Asparagine is an amino acid found incorporated into most proteins, and protein synthesis is halted in its absence, thereby inhibiting RNA and DNA synthesis with a resulting halt to cellular proliferation.
As lymphoblastic cells are lacking asparagine synthetase activity they are dependent upon exogenous asparagine. The anti-tumor activity of L-asparaginase is a result of the sustained depletion of exogenous asparagine.
It has also been noted that asparaginase, in addition to its asparaginase activity, has significant glutaminase activity. It catalyzes the deamination of glutamine in glutamic acid with the release of ammonia.
Glutamine may lead to alternative asparagine synthesis and therefore glutamine depletion may complement asparagine depletion. However, exact potential of this glutaminase activity remains unknown.
|Indication||Erwinase is indicated as a component of a chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia (ALL) who have developed hypersensitivity to E. coli-derived asparaginase. Erwinase is indicated in pediatric patients from the age of 4 months and in adults.|
|Strengths||Crisantaspase (L-asparaginase from Erwinia chrysanthemi), 10,000 International units/vial|